Leisure Acquisition Corp. (NASDAQ:LACQU): Thomas Lenox Kempner, Jr.’s Davidson Kempner Partners filed an amended 13D.
You can check out Davidson Kempner Partners’ latest holdings and filings here.
Please follow Davidson Kempner Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Davidson Kempner Partners or update its stock holdings.
Follow Thomas Lenox Kempner And Anthony Yoseloff's Davidson Kempner
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Davidson Kempner Partners | 0 | 272,850 | 0 | 272,850 | 272,850 | 1.06% |
| Davidson Kempner Institutional Partners | 0 | 578,850 | 0 | 578,850 | 578,850 | 2.25% |
| Davidson Kempner International, Ltd | 0 | 648,300 | 0 | 648,300 | 648,300 | 2.52% |
| Davidson Kempner Capital Management | 0 | 1,500,000 | 0 | 1,500,000 | 1,500,000 | 5.83% |
| Thomas L. Kempner, Jr | 0 | 1,500,000 | 0 | 1,500,000 | 1,500,000 | 5.83% |
| Robert J. Brivio, Jr | 0 | 1,500,000 | 0 | 1,500,000 | 1,500,000 | 5.83% |
Page 1 of 12 – SEC Filing
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| SCHEDULE 13G | |
| Under the Securities Exchange Act of 1934 | |
| (Amendment No. __)* | |
| Leisure Acquisition | |
| (Name of Issuer) | |
| Common Stock, | |
| (Title of Class of Securities) | |
| 52539T206** | |
| (CUSIP Number) | |
| December | |
| (Date of Event Which Requires Filing of this Statement) | |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: | |
| ¨ | Rule 13d-1(b) |
| ý | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
| (Page 1 of 12 Pages) | |
______________________________
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
**The Common Stock has no CUSIP number.
The CUSIP number for the units which include the Common Stock is 52539T206.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 2 of 12 – SEC Filing
| 1 | NAME OF REPORTING PERSON Davidson Kempner Partners | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ý | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION New York | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | ||
| 6 | SHARED VOTING POWER 272,850 | |||
| 7 | SOLE DISPOSITIVE POWER 0 | |||
| 8 | SHARED DISPOSITIVE POWER 272,850 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 272,850 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.06% | |||
| 12 | TYPE OF REPORTING PERSON PN | |||
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 3 of 12 – SEC Filing
| 1 | NAME OF REPORTING PERSON Davidson Kempner Institutional Partners, L.P. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ý | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | ||
| 6 | SHARED VOTING POWER 578,850 | |||
| 7 | SOLE DISPOSITIVE POWER 0 | |||
| 8 | SHARED DISPOSITIVE POWER 578,850 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 578,850 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.25% | |||
| 12 | TYPE OF REPORTING PERSON PN | |||
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 4 of 12 – SEC Filing
| 1 | NAME OF REPORTING PERSON Davidson Kempner International, Ltd. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ý | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | ||
| 6 | SHARED VOTING POWER 648,300 | |||
| 7 | SOLE DISPOSITIVE POWER 0 | |||
| 8 | SHARED DISPOSITIVE POWER 648,300 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 648,300 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.52% | |||
| 12 | TYPE OF REPORTING PERSON CO | |||
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 5 of 12 – SEC Filing
| 1 | NAME OF REPORTING PERSON Davidson Kempner Capital Management LP | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ý | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | ||
| 6 | SHARED VOTING POWER 1,500,000 | |||
| 7 | SOLE DISPOSITIVE POWER 0 | |||
| 8 | SHARED DISPOSITIVE POWER 1,500,000 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,500,000 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.83% | |||
| 12 | TYPE OF REPORTING PERSON PN | |||
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 6 of 12 – SEC Filing
| 1 | NAME OF REPORTING PERSON Thomas L. Kempner, Jr. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ý | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | ||
| 6 | SHARED VOTING POWER 1,500,000 | |||
| 7 | SOLE DISPOSITIVE POWER 0 | |||
| 8 | SHARED DISPOSITIVE POWER 1,500,000 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,500,000 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.83% | |||
| 12 | TYPE OF REPORTING PERSON IN | |||
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 7 of 12 – SEC Filing
| 1 | NAME OF REPORTING PERSON Robert J. Brivio, Jr. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ý | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | ||
| 6 | SHARED VOTING POWER 1,500,000 | |||
| 7 | SOLE DISPOSITIVE POWER 0 | |||
| 8 | SHARED DISPOSITIVE POWER 1,500,000 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,500,000 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.83% | |||
| 12 | TYPE OF REPORTING PERSON IN | |||
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 8 of 12 – SEC Filing
| Item 1(a). | NAME OF ISSUER |
| Leisure Acquisition Corp. (the “Issuer“) | |
| Item 1(b). | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES |
| 250 West 57th Street, Suite 2223, New York, New York 10107 | |
| Item 2(a). | NAME OF PERSON FILING |
| This Statement is filed by each of the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons“: |
| (i) | Davidson Kempner Partners, a New York limited partnership (“DKP“). MHD Management Co., a New York limited partnership (“MHD“), is the general partner of DKP and MHD Management Co. GP, L.L.C., a Delaware limited liability company, is the general partner of MHD. DKCM is responsible for the voting and investment decisions of DKP; | |
| (ii) | Davidson Kempner Institutional Partners, L.P., a Delaware limited partnership (“DKIP“). Davidson Kempner Advisers Inc., a New York corporation, is the general partner of DKIP. DKCM is responsible for the voting and investment decisions of DKIP; | |
| (iii) | Davidson Kempner International, Ltd., a British Virgin Islands business company (“DKIL“). DKCM is the investment manager of DKIL and is responsible for the voting and investment decisions of DKIL; | |
| (iv) | Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission, acts as investment manager to each of DKP, DKIP and DKIL (“DKCM“). DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Thomas L. Kempner, Jr., Robert J. Brivio, Jr., Eric P. Epstein, Anthony A. Yoseloff, Avram Z. Friedman, Conor Bastable, Morgan P. Blackwell, Shulamit Leviant, Patrick W. Dennis and Gabriel T. Schwartz; and | |
| (v) | Messrs. Thomas L. Kempner, Jr. and Robert J. Brivio, Jr. through DKCM, are responsible for the voting and investment decisions relating to the securities held by DKP, DKIP and DKIL reported herein. |
| Item 2(b). | ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE |
| The address of the principal business office of each of the Reporting Persons is c/o Davidson Kempner Capital Management LP, 520 Madison Avenue, 30th Floor, New York, New York 10022. |
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 9 of 12 – SEC Filing
| Item 2(c). | CITIZENSHIP |
| (i) | DKP – a New York limited partnership | |
| (ii) | DKIP – a Delaware limited partnership | |
| (iii) | DKIL – a British Virgin Islands business company | |
| (iv) | DKCM – a Delaware limited partnership | |
| (v) | Messrs. Thomas L. Kempner, Jr. and Robert J. Brivio, Jr. – United States | |
| Item 2(d). | TITLE OF CLASS OF SECURITIES |
| Common Stock, par value $0.0001 per share (the “Common Stock“) |
| Item 2(e). | CUSIP NUMBER |
| The Common Stock has no CUSIP number. The CUSIP number for the units which include the Common Stock is 52539T206. |
| Item 3. | IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: |
| (a) | ¨ | Broker or dealer registered under Section 15 of the Act; | |
| (b) | ¨ | Bank as defined in Section 3(a)(6) of the Act; | |
| (c) | ¨ | Insurance company as defined in Section 3(a)(19) of the Act; | |
| (d) | ¨ | Investment company registered under Section 8 of the Investment Company Act of 1940; | |
| (e) | ¨ | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); | |
| (f) | ¨ | An employee benefit plan or endowment fund in | |
| (g) | ¨ | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); | |
| (h) | ¨ | A savings association as defined in Section 3(b) | |
| (i) | ¨ | A church plan that is excluded from the definition |
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 10 of 12 – SEC Filing
| (j) | ¨ | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); | |
| (k) | ¨ | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
| If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________ | |
| Item 4. | OWNERSHIP. |
| The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. | |
| The percentages used in this Schedule 13G are calculated based upon the 25,750,000 shares of Common Stock reported to be outstanding in the Issuer’s Prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission on December 1, 2017 after giving effect to the completion of the offering, as described therein. | |
| Item 5. | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS |
| Not applicable. | |
| Item 6. | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON |
| Not applicable. | |
| Item 7. | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON |
| Not applicable. | |
| Item 8. | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP |
| Not applicable. | |
| Item 9. | NOTICE OF DISSOLUTION OF GROUP |
| Not applicable. | |
| Item 10. | CERTIFICATION |
| Each of the Reporting Persons hereby makes the following certification: | |
| By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 11 of 12 – SEC Filing
SIGNATURES
After reasonable
inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.
DATE: December 11, 2017
| davidson kempner partners | |
| By: MHD Management Co., | |
| its General Partner | |
| By: MHD Management Co. GP, L.L.C., | |
| its General Partner | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: Executive Managing Member | |
| DAVIDSON KEMPNER institutional partners, L.P. | |
| By: Davidson Kempner Advisers Inc., | |
| its General Partner | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: President | |
| davidson kempner international, ltd. | |
| By: Davidson Kempner Capital Management LP, | |
| its Investment Manager | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: Executive Managing Member | |
| davidson kempner CAPITAL MANAGEMENT LP | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: Executive Managing Member | |
| /s/ Thomas L. Kempner, Jr. | |
| THOMAS L. KEMPNER, JR. | |
| /s/ Robert J. Brivio, Jr. | |
| ROBERT J. BRIVIO, JR. |
Follow Ensysce Biosciences Inc.
Follow Ensysce Biosciences Inc.
Page 12 of 12 – SEC Filing
JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge
and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments
to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional
joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and
for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible
for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason
to believe that such information is inaccurate.
DATE:
December 11, 2017
| davidson kempner partners | |
| By: MHD Management Co., | |
| its General Partner | |
| By: MHD Management Co. GP, L.L.C., | |
| its General Partner | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: Executive Managing Member | |
| DAVIDSON KEMPNER institutional partners, L.P. | |
| By: Davidson Kempner Advisers Inc., | |
| its General Partner | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: President | |
| davidson kempner international, ltd. | |
| By: Davidson Kempner Capital Management LP, | |
| its Investment Manager | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: Executive Managing Member | |
| davidson kempner CAPITAL MANAGEMENT LP | |
| /s/ Thomas L. Kempner, Jr. | |
| Name: Thomas L. Kempner, Jr. | |
| Title: Executive Managing Member | |
| /s/ Thomas L. Kempner, Jr. | |
| THOMAS L. KEMPNER, JR. | |
| /s/ Robert J. Brivio, Jr. | |
| ROBERT J. BRIVIO, JR. |
